Mast Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company leverages its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188, the Company’s lead product candidate. MST-188 has demonstrated multiple pharmacologic effects that provide clinical benefit in a range of diseases and conditions characterized by impaired microvascular blood flow and damaged cell membranes. MST-188 has orphan drug status for the treatment of sickle cell disease in the U.S. and European Union. The Company’s pipeline includes MST-188 development programs in adjunctive thrombolytic therapy, such as acute limb ischemia, stroke; heart failure, and resuscitation following trauma, such as restoration of circulating blood volume and pressure. The product is in Phase 2a of its clinical trial.